Details of the Drug Combination

General Information of Drug Combination (ID: DCDU3HX)

Drug Combination Name
MK-1775 RTB101
Indication
Disease Entry Status REF
Invasive ductal carcinoma Investigative [1]
Component Drugs MK-1775   DM3WDZ5 RTB101   DM62QTW
Small molecular drug Small molecular drug
High-throughput Screening Result Testing Cell Line: T-47D
Zero Interaction Potency (ZIP) Score: 5.43
Bliss Independence Score: 7.04
Loewe Additivity Score: 8.8
LHighest Single Agent (HSA) Score: 10.05

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of MK-1775
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
MK-1775 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Wee1-like protein kinase (WEE1) TTJFOAL WEE1_HUMAN Inhibitor [7]
------------------------------------------------------------------------------------
MK-1775 Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Decreases Phosphorylation [6]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Response To Substance [6]
------------------------------------------------------------------------------------
Indication(s) of RTB101
Disease Entry ICD 11 Status REF
Respiratory tract infection CA45 Phase 3 [4]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [5]
RTB101 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
CREB-regulated transcription coactivator 1 (TORC1) TT4GO0F CRTC1_HUMAN Inhibitor [8]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DCYFEOJ NCIH2122 Investigative [9]
Adenocarcinoma DCYBXH5 NCIH520 Investigative [9]
Adenocarcinoma DCXSHM2 COLO320DM Investigative [9]
Adenocarcinoma DCU4EYH DLD1 Investigative [9]
Adenocarcinoma DCWZQV8 HCT116 Investigative [9]
Adenocarcinoma DCZXAT9 HT29 Investigative [9]
Adenocarcinoma DC8VZYT SW-620 Investigative [9]
Ewing sarcoma-peripheral primitive neuroectodermal tumour DCR0DKK ES2 Investigative [9]
Germ cell tumour DCG0FU7 PA1 Investigative [9]
Malignant melanoma DCMRDUC A375 Investigative [9]
Malignant melanoma DCFOKO1 HT144 Investigative [9]
Malignant melanoma DCB5IYJ RPMI7951 Investigative [9]
Malignant melanoma DC2TQK3 SKMEL30 Investigative [9]
Mesothelioma DCN9LZK MSTO Investigative [9]
Non small cell carcinoma DCVY5FW SKMES1 Investigative [9]
Ovarian endometrioid adenocarcinoma DC8BRH3 A2780 Investigative [9]
Prostate carcinoma DCK432M LNCAP Investigative [9]
Prostate carcinoma DCFXWB4 VCAP Investigative [9]
Breast carcinoma DCXGPKA ZR751 Investigative [1]
Breast carcinoma DC0HHQV OCUBM Investigative [1]
Carcinoma DCPXFEZ EFM192B Investigative [1]
Carcinoma DCLY0HZ MDAMB436 Investigative [1]
Colon adenocarcinoma DC1BAGP LOVO Investigative [1]
Colon carcinoma DCYH32Q RKO Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 24 DrugCom(s)

References

1 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7702).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT04139915) Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly. U.S. National Institutes of Health.
5 ClinicalTrials.gov (NCT04409327) Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes. U.S. National Institutes of Health.
6 Functional kinomics identifies candidate therapeutic targets in head and neck cancer. Clin Cancer Res. 2014 Aug 15;20(16):4274-88. doi: 10.1158/1078-0432.CCR-13-2858.
7 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
8 Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
9 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.